Target
PKC delta
2 abstracts
Abstract
A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.Org: Queensland Institute of Medical Research Berghofer, Royal Victorian Eye and Ear Hospital, St. Vincent's Pathology, Terrace Eye Centre, The Alfred/Monash University,
Abstract
NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).Org: Royal Victorian Eye and Ear Hospital, Melbourne, Australia, University of Sydney, Sydney, Australia, Princess Alexandra Hospital, Greenslopes Private Hospital and University of Queensland, Brisbane, Australia, Queensland Institute of Medical Research Berghofer, Herston, Australia, Terrace Eye Centre, Brisbane, Australia,